At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Cohort Study to Define Infectious Burden, the Seroprevalence of Vaccine Preventable Pathogens and Immune Recovery in the First Year Following Completion of Therapy in Patients With Acute Lymphoblastic Leukemia (ALL)
In Brief
An observational study evaluating Observational only: Serology and flow cytometry for ALL cohort participants and Observational only: Infection rates for Acute Lymphoblastic Leukemia, Pediatric. Completed, enrolled 89 participants across 6 sites.
Detailed Summary
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.
Study Details
Timeline
Interventions
Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
Number of infections during the study period will be obtained and infection incidence rates calculated during the first year off-chemotherapy.